Previous close | 64.59 |
Open | 64.59 |
Bid | 64.91 x 1100 |
Ask | 64.92 x 1100 |
Day's range | 64.36 - 64.94 |
52-week range | 61.73 - 76.56 |
Volume | |
Avg. volume | 5,523,217 |
Market cap | 201.225B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 34.35 |
EPS (TTM) | 1.89 |
Earnings date | N/A |
Forward dividend & yield | 1.45 (2.25%) |
Ex-dividend date | 10 Aug 2023 |
1y target est | 82.69 |
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
Presage Biosciences, a pioneering translational oncology company whose mission is to use CIVO and spatial molecular profiling to understand the complexity of drug response in the tumor microenvironment (TME), has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company. According to the agreement, Presage's platform will be used by AstraZeneca in translational analysis to evaluate several investigational bispecific antibody combinations in samples take
In this article, we will be navigating through the living conditions across Europe while covering the 17 best European countries to move to from the USA. If you wish to skip our detailed analysis, you can move directly to the 5 Best European Countries to Move to from the USA. Life in Europe: An Overview […]